Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933740 | 0.86 | MAPT (0.68) | MAPTKCNK3LMNAP2RX1MEN1 | |
| SCHEMBL30523366 | 0.86 | MAPT (0.68) | MAPTKCNK3LMNAP2RX1MEN1 | |
| SCHEMBL24141032 | 0.84 | MAPT (0.84) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL17103527 | 0.84 | MAPT (0.70) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL16035764 | 0.84 | MAPT (0.65) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL16034660 | 0.84 | MAPT (0.65) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL16036025 | 0.84 | MAPT (0.65) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL4286068 | 0.83 | MAPT (0.94) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL23447711 | 0.83 | MAPT (0.82) | MAPTKCNK3LMNAP2RX1RXFP1 | |
| SCHEMBL15879845 | 0.83 | MAPT (0.64) | MAPTKCNK3LMNAP2RX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557996-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-1802586-B1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | MAPT 4468/4885KCNK3 773/4885LMNA 1665/4885 |
| US-20060217380-A1 | Heteroaryl-substituted alkyne compounds and method of use | IRAK3, IRAK1, MAP3K1 | MAPT 4468/4885KCNK3 773/4885LMNA 1665/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | MAPT 4333/4885KCNK3 835/4885LMNA 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.